Purple Book Companion™ (beta) Announcement

In a January, 2021 Orange Book Insights posting, I reported that the Purple Book for biologic products might soon start including patents. Based upon that news, I was looking forward to creating an enhanced way to look at biologics patents in the same way that my Orange Book Companion® gives users an enhanced way of looking at Orange Book patents. 

So I am now happy to announce the availability of a beta version of my Purple Book Companion™ (“PBC”)! Since this is a beta, it is free for everyone to use. So please take advantage of this offer, and please send any comments, questions, or suggestions that you might have to the email address found on the PBC homepage.

Since Purple Book patent listings are fairly new, and were only required on a prospective basis, there are not a lot of such listings. In fact, there are only four products for which patents have been submitted to the FDA:

* Avastin® (from Genentech): 22 patents

* Humira® (from Abbvie): 65 patents

* Lucentis® (from Genentech): 11 patents, and

* Neulasta®/Neulasta® Onpro (from Amgen): 1 patent

Before patents were listed in the Purple Book, there were already exclusivity listings in the Purple Book. So the PBC also includes those. I found three types of exclusivity that are listed in the FDA’s current Purple Book data:

* Reference Product Exclusivity: 13 products

* Interchangeable Product Exclusivity: 2 products

* Orphan Drug Exclusivity: 176 products

The FDA’s Purple Book data contains some expired exclusivities. In this beta version, I did not do anything to remove them. For the Orange Book, the FDA removes expired patents and exclusivities on an annual basis when they release Supplement 1 of the latest Orange Book volume each February.

The FDA’s Purple Book data does not include any information on the Orphan Drug indication that is protected by the exclusivity. The FDA’s Orange Book currently includes numbered descriptions of orphan indications for small molecule drugs. Prior to the FDA’s addition of those numbered Orphan Drug descriptions to the Orange Book, I used a system for my Orange Book Companion by which I extracted the descriptions from the FDA’s Orphan Drug database.

For most PBC products, I managed to resurrect my prior system so that users of the Purple Book Companion can have that additional information. Unfortunately, due to slight differences that sometimes occur between the contents of the “Proprietary Name” and “Trade Name” fields in the Purple Book and in the Orphan Drug Database, respectively, my automated retrieval of orphan indications from the FDA's Orphan Drug Database might not succeed in all cases. So before making a business critical decision, always double check the official source, such as FDA’s Orphan Drug Database. However, since the Purple Book’s orphan drug data only includes the date of the last-to-expire orphan exclusivity for a drug, my automated extraction system will provide you with most, if not all, of the many orphan indications and their expiration dates that could currently be protecting a drug.

I hope that everyone who is interested in patents and exclusivities for biologic products will find my Purple Book Companion useful.  Please feel free to send me any comments, questions, and suggestions that you might have to the email address found on the PBC homepage.

#patents #fda #hatchwaxman  #drugpatents #orangebook #orangebookpatents #orangebookinsights #orangebookcompanion #purplebook #biologics #purplebookcompanion #BPCIA


Comments

Post a Comment

Popular posts from this blog

Orange Book Vol. 42/Supp. 6 News: Watch out for the breadth of your use codes

This posting is late since I am talking about Vol. 42, Supp. 6 of the Orange Book. The data for Supp. 6 was released by the FDA in mid-July. However, I updated my  Orange Book Companion  immediately when the data was released, so my subscribers received the new data on time. Similarly, if you are not a subscriber but enjoy checking out my free  Orange Book Companion  “ What’s New ” each month, that was also ready to view in mid-July. So, what is late? It’s this Supp. 6 news where I discuss a mass delisting of patents for a single product   in which all of the patents had what appears to be overly broad use codes . Please read on.   Supp. 6 added 52 new patents to the FDA’s Orange Book. However, unlike Supp. 5, there were a number of patents that were delisted or were newly tagged as being the subject of a delisting request. Two of four patents listed for Serenity Pharmaceuticals’ NOCTIVA ( desmopressin acetate)   were delisted. Both strengths of NOCTIVA are shown in the Orange Book as
Read more

Orange Book V43, Supp. 1 news

  Happy Orange Book New Year! Volume 43, Supp. 1 added 41 new patents to the FDA’s Orange Book. That includes three new patents for the current patent listing champ, AUVELITY® which now has 103 patents listed. You can see all of the changes to the Orange Book that occurred in Vol. 43/Supp. 1 by going to the Orange Book Companion® public home page and clicking on the prominent “What’s New” link.  If are a gluten for punishment, can also see all 103 AUVELITY patents by clicking the sample link for trademarks that begin with "A" and then scrolling down to AUVELITY. A device for making a drug does not claim the drug, itself Three particularly interesting patents were listed in the Orange Book as part of Volume 43/Supplement 1. All three patents claim devices for making the approved drug. They do not claim the approved drug, itself, or a method of using the approved drug. Yet all three were listed as “drug product” patents.  In each case, the approved product is a gas that is con
Read more

Make sure that your patent exists before submitting a 3542 form for the patent to the FDA

 So, you received an “Issue Notification” from the USPTO for an allowed patent application. Yay! But be careful! The “Issue Notification” document that the USPTO sent you says that it merely contains a “ projected ” patent number and issue date.  In the case of MC2 Therapeutics’ WYNZORA, a patent with the projected patent number that the Issue Notification contained did not issue on the projected issue date, and, in fact, never issued! However, MC2 must have submitted a 3542 form to the FDA for patent number 11638711 (‘711 patent) that was contained in an Issue Notification that had been sent to them on April 12, 2023. That Issue Notification said that the patent would issue on May 2, 2023. The Electronic Orange Book shows that information for the ‘711 patent was received by the FDA for WYNZORA on May 31. However, in my preparation for the Vol. 43/ Supplement 6 version of my Orange Book Companion® I discovered that one of the text files of basic data that my algorithms had generated fo
Read more